Literature DB >> 17307255

Interferon-alpha treatment of hepatitis D induces tuberculosis exacerbation in an immigrant.

Claudia Telesca1, Mario Angelico, Paola Piccolo, Lorenzo Nosotti, Aldo Morrone, Chiara Longhi, Marco Carbone, Leonardo Baiocchi.   

Abstract

This report describes the case of a young Romanian patient who developed a severe exacerbation of pulmonary tuberculosis during interferon-alpha treatment for chronic hepatitis D. While this occurrence underscores that clinical guidelines should be applied with caution in immigrants from underdeveloped countries, due to the possible presence of unrecognized or unreported comorbidity, the mechanisms for an interferon-related exacerbation of pulmonary tuberculosis are also examined. We propose that IFN-induced weight loss and anorexia may have played an important role in promoting clinical manifestations of tuberculosis in our patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17307255     DOI: 10.1016/j.jinf.2006.12.009

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  19 in total

1.  The impact of ISGylation during Mycobacterium tuberculosis infection in mice.

Authors:  Jacqueline M Kimmey; Jessica A Campbell; Leslie A Weiss; Kristen J Monte; Deborah J Lenschow; Christina L Stallings
Journal:  Microbes Infect       Date:  2017-01-10       Impact factor: 2.700

2.  TLR2 signaling depletes IRAK1 and inhibits induction of type I IFN by TLR7/9.

Authors:  Yi C Liu; Daimon P Simmons; Xiaoxia Li; Derek W Abbott; W Henry Boom; Clifford V Harding
Journal:  J Immunol       Date:  2012-01-06       Impact factor: 5.422

3.  Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9.

Authors:  Daimon P Simmons; David H Canaday; Yi Liu; Qing Li; Alex Huang; W Henry Boom; Clifford V Harding
Journal:  J Immunol       Date:  2010-07-21       Impact factor: 5.422

4.  Role of interleukin 6 in innate immunity to Mycobacterium tuberculosis infection.

Authors:  Alejandra N Martinez; Smriti Mehra; Deepak Kaushal
Journal:  J Infect Dis       Date:  2013-01-28       Impact factor: 5.226

5.  Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis.

Authors:  Ludovic Desvignes; Andrea J Wolf; Joel D Ernst
Journal:  J Immunol       Date:  2012-05-07       Impact factor: 5.422

6.  An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis.

Authors:  Matthew P R Berry; Christine M Graham; Finlay W McNab; Zhaohui Xu; Susannah A A Bloch; Tolu Oni; Katalin A Wilkinson; Romain Banchereau; Jason Skinner; Robert J Wilkinson; Charles Quinn; Derek Blankenship; Ranju Dhawan; John J Cush; Asuncion Mejias; Octavio Ramilo; Onn M Kon; Virginia Pascual; Jacques Banchereau; Damien Chaussabel; Anne O'Garra
Journal:  Nature       Date:  2010-08-19       Impact factor: 49.962

Review 7.  Pattern recognition receptors and cytokines in Mycobacterium tuberculosis infection--the double-edged sword?

Authors:  Md Murad Hossain; Mohd-Nor Norazmi
Journal:  Biomed Res Int       Date:  2013-11-12       Impact factor: 3.411

8.  STING-dependent type I IFN production inhibits cell-mediated immunity to Listeria monocytogenes.

Authors:  Kristina A Archer; Juliana Durack; Daniel A Portnoy
Journal:  PLoS Pathog       Date:  2014-01-02       Impact factor: 6.823

9.  Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: a population-based cohort study in Taiwan.

Authors:  Shang-Yi Lin; Tun-Chieh Chen; Po-Liang Lu; Chun-Yu Lin; Wei-Ru Lin; Yi-Hsin Yang; Yen-Hsu Chen
Journal:  BMC Infect Dis       Date:  2014-12-19       Impact factor: 3.090

10.  Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics.

Authors:  Anca Dorhoi; Vladimir Yeremeev; Geraldine Nouailles; January Weiner; Sabine Jörg; Ellen Heinemann; Dagmar Oberbeck-Müller; Julia K Knaul; Alexis Vogelzang; Stephen T Reece; Karin Hahnke; Hans-Joachim Mollenkopf; Volker Brinkmann; Stefan H E Kaufmann
Journal:  Eur J Immunol       Date:  2014-06-24       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.